Category: Business

Mati Therapeutics Interim Phase II Nepafenac Clinical Trial Results Signal Significant Post-op Pain Reduction in Cataract Surgery Patients

AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that it has completed a planned interim analysis of an ongoing Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute® sustained ocular drug delivery platform. The trial is a multi-center, randomized, masked evaluation of nepafenac vs. placebo in 75 patients undergoing cataract surgery. The primary endpoint is to evaluate pain and the secondary endpoint is to evalua

Second Sight Appoints Pat Ryan Chief Operating Officer

SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today that Pat Ryan has been appointed Chief Operating Officer, effective immediately. In this newly created role, Mr. Ryan will assume responsibility for Research & Development, Manufacturing, Planning & Ma

2020 On-site appoints Alexis McLaughlin as Chief Executive Officer, Closes Over $5MM in Series B Financing and Named to the Inc. 5000

BOSTON–(BUSINESS WIRE)–#HR–2020 On-site (2020), America’s leading provider of on-site vision care for businesses and schools, serving over 450 leading employers, announced this morning the appointment of Alexis McLaughlin as 2020’s new Chief Executive Officer. McLaughlin will also join 2020’s Board of Directors. Most recently, McLaughlin was SVP/General Manager of Retail Licensed Brands at Luxottica Retail, where she was responsible for $500MM in revenue across 1,000 stores in North America. In h

Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule

DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (NASDAQ:HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED). The study (NCT03298867 and EudraCT 2017-002763-18) enrolled 83 patients at 13 sites across the United States, Germany and Italy. Topline results are expected in the second quarter of 2019. “Our success in rapidly enrolling this trial speaks to the significant unmet ne

Patient-Driven Gene Therapy Company ReflectionBio Receives Orphan Drug Designation From U.S. FDA For the Treatment of Bietti’s Crystalline Dystrophy (BCD)

HONG KONG & NEW YORK–(BUSINESS WIRE)–Reflection Biotechnologies Limited (“ReflectionBio”), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ReflectionBio’s RBIO-101 program (AAV.CYP4V2), an AAV-based gene therapy product for treating Bietti’s Crystalline Dystrophy (BCD). “Receiving orphan drug designation from the FDA is a miles

EyeSouth Expands into South Florida Through Affiliation with Florida Eye Microsurgical Institute

ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed a strategic partnership with Florida Eye Microsurgical Institute and Boynton Beach ASC (“Florida Eye Microsurgical”), expanding its presence into the South Florida region. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a leading lower middle market healthcare private equity firm. Florida Eye Microsurgical is led by ophthalmolog